Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles

RESEARCH ARTICLE

Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience

Anil Bhansali, Anish Bhattacharya, Ashwani Sood, Baljinder Singh, Bhagwant Rai Mittal, Kanhaiyalal Agrawal, Jaya Shukla

Citation Information : Bhansali A, Bhattacharya A, Sood A, Singh B, Mittal BR, Agrawal K, Shukla J. Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience. J Postgrad Med Edu Res 2013; 47 (1):1-6.

DOI: 10.5005/jp-journals-10028-1049

Published Online: 00-03-2013

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, majority of which express somatostatin (SST) receptors. Recently, with the widespread use of positron emission tomography/computed tomography (PET/CT) and development of novel PET tracers like Ga-68 DOTA peptide which specifically bind to somatostatin receptors (SSTR), Ga-68 DOTA peptide PET/CT is used in management of NET.

Objective

To study the various indications for which Ga-68 DOTATATE PET/CT scan was performed and the utility of the scans.

Materials and methods

Retrospective evaluation of the patients data was performed who underwent Ga-68 DOTATATE PET/CT as part of their diagnostic workup between June 2011 and July 2012. A total of 145 patients aged 1 to 71 years (mean: 37.4 years) were studied during this period.

Results

Ga-68 DOTATATE PET scan was positive in 23/39 patients referred for characterization or diagnosis, in 6/19 patients for localization, in 13/24 patients for detection of unknown NET primary, in 16/17 patients for staging, in 6/7 patients for recurrence assessment, 12/12 patients for response evaluation, 7/18 patients in restaging and in 5/5 differentiated thyroid cancer patients with thyroglobulin elevated but negative iodine scan.

Conclusion

Ga-68 DOTATATE PET/CT is a useful modality in characterization, localization, detection of unknown NET primary, staging, restaging, recurrence and response evaluation to treatment in patients with NET.

How to cite this article

Mittal BR, Agrawal K, Shukla J, Bhattacharya A, Singh B, Sood A, Bhansali A. Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience. J Postgrad Med Edu Res 2013;47(1):1-6.


PDF Share
  1. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15-27.
  2. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med 2001;28:1751-57.
  3. Evaluation of positron emission tomography imaging using 68Ga-DOTA-D-Phe 1-Tyr3-octreotide in comparison to [111 In]-DTPAOC SPECT: First results in patients with neuroendocrine tumors. Mol Imag Biol 2003;5:42-48.
  4. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18.
  5. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
  6. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80(Suppl 1):3-7.
  7. One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
  8. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995 Jul;25(3):251-61.
  9. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):S51-61.
  10. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-58.
  11. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
  12. Concomitant expression of several peptide receptors in neuroendocrine tumors: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imag 2003;30:781-93.
  13. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imag 2010;37:46-48.
  14. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imag 2010;37:49-57.
  15. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55.
  16. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imag 2008;35:1431-38.
  17. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008;62:667-71.
  18. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-32.
  19. 68Ga-DOTA-NOC: A new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281-86.
  20. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 1998;39:1913-17.
  21. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46: 763-69.
  22. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imag 2007;34:982-93.
  23. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imag 2010;37:67-77.
  24. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
  25. (68)Ga-DOTANOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imag 2010;37:722-27.
  26. 68Ga-DOTATyr3-octreotide PET for assessing response to somatostatinreceptor-mediated radionuclide therapy. J Nucl Med 2009;50: 1427-34.
  27. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002;29:147-57.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.